García-Erce J A, Cuenca J, Muñoz M, Izuel M, Martínez A A, Herrera A, Solano V M, Martínez F
Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain.
Vox Sang. 2005 May;88(4):235-43. doi: 10.1111/j.1423-0410.2005.00627.x.
Patients undergoing surgery for hip fracture (HF) often receive perioperative allogeneic blood transfusions (ABT) to avoid anaemia. However, concerns about the adverse effects of ABT have prompted the review of transfusion practice and the search for a safer treatment of perioperative anaemia.
We prospectively investigated the effect of a blood-saving protocol of perioperative iron sucrose (3 x 200 mg/48 h, intravenously) plus erythropoietin (1 x 40,000 IU, subcutaneously) if admission haemoglobin level < 130 g/l, on transfusion requirements and postoperative morbid-mortality in patients with HF (group 2; n= 83). A parallel series of 41 HF patients admitted to another surgical unit within the same hospital served as the control group (group 1). Perioperative blood samples were taken for haematimetric, iron metabolism and inflammatory parameter determination.
This blood-saving protocol reduced the number of transfused patients (P < 0.001), the number of transfused units (P < 0.0001), increased the reticulocyte count and improved iron metabolism. In addition, the blood-saving protocol also reduced the rate of postoperative infections (P = 0.016), but not the 30-day mortality rate or the mean length of hospital stay.
The blood-saving protocol implemented seems to reduce ABT requirements in patients with HF, and is associated with a lower postoperative morbidity. The possible mechanisms involved in these effects are discussed.
髋部骨折(HF)手术患者常接受围手术期异体输血(ABT)以避免贫血。然而,对ABT不良反应的担忧促使人们重新审视输血实践,并寻求更安全的围手术期贫血治疗方法。
我们前瞻性研究了一种血液保护方案的效果,该方案为:若入院时血红蛋白水平<130g/l,则围手术期静脉注射蔗糖铁(3×200mg/48h)加皮下注射促红细胞生成素(1×40,000IU),观察其对HF患者(第2组;n = 83)输血需求及术后病死-发病率的影响。同一医院另一个外科病房收治的41例HF患者作为平行对照组(第1组)。采集围手术期血样以测定血液学、铁代谢和炎症参数。
该血液保护方案减少了输血患者数量(P < 0.001)、输血量(P < 0.0001),增加了网织红细胞计数并改善了铁代谢。此外,该血液保护方案还降低了术后感染率(P = 0.016),但未降低30天死亡率或平均住院时间。
实施的血液保护方案似乎可降低HF患者的ABT需求,并与较低的术后发病率相关。文中讨论了这些效果可能涉及的机制。